CHEPLAPHARM Arzneimittel GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CHEPLAPHARM Arzneimittel GmbH - overview
Established
1998
Location
Greifswald, -, Germany
Primary Industry
Pharmaceuticals
About
CHEPLAPHARM Arzneimittel GmbH is a pharmaceutical company specializing in the acquisition and development of established brands, focusing on specialty pharma to enhance accessibility in global healthcare markets. Founded in 1998 and headquartered in Greifswald, Germany, CHEPLAPHARM Arzneimittel GmbH specializes in pharmaceuticals, particularly in the acquisition and development of established brands. The company has undergone strategic growth and expansion, particularly noted in its recent financial activities. In October 2022, a Growth round raised EUR 550 million, facilitated by investors Atlantic Park and GIC, marking a significant investment target for enhancing their portfolio.
The firm has completed two notable deals, with the most recent deal taking place in October 2022. The current CEO, Edeltraud Lafer, leads the company in its mission to promote healthcare accessibility. CHEPLAPHARM Arzneimittel GmbH specializes in acquiring and developing established pharmaceutical brands from research-based companies, focusing on specialty pharma. Their diverse range of prescription medications covers therapeutic areas, including dermatology, oncology, and cardiology, ensuring safety and efficacy to meet healthcare professionals' needs.
The company aims to enhance market accessibility for these established brands across Europe, Asia, and select regions in the Americas, serving healthcare providers, pharmacies, and hospitals with effective treatments. In 2022, CHEPLAPHARM Arzneimittel GmbH reported a revenue of EUR 1,348,308,288. 50 and an EBITDA of EUR 722,575,149. 70.
The company generates revenue through partnerships with pharmaceutical firms, acquiring rights to market established products and engaging in business-to-business transactions with healthcare providers and pharmacies, utilizing a pricing structure aligned with industry standards. Looking ahead, CHEPLAPHARM Arzneimittel GmbH plans to leverage the recent EUR 550 million investment to accelerate its growth initiatives and enhance its pharmaceutical solutions across the healthcare industry. The company is focused on expanding its presence in new global markets, specifically targeting growth in Asia and North America by 2025. This strategic capital injection will facilitate the development and launch of new products that are currently in the pipeline, aimed at increasing their therapeutic offerings.
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals
Website
www.cheplapharm.com
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
CHEPLAPHARM Arzneimittel GmbH - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Announced | CHEPLAPHARM Arzneimittel GmbH | - | ||||||||
| Private Debt | Completed | CHEPLAPHARM Arzneimittel GmbH | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.